Cargando...
Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2
Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are immunotherapies that target various B cell–related proteins. Most of these treatments have proven efficacy in relapsing and progressive forms of MS and neuromyelitis optica spectrum disease (NMOSD) or are in advanced...
Gardado en:
| Publicado en: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Lippincott Williams & Wilkins
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8063618/ https://ncbi.nlm.nih.gov/pubmed/33411674 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000919 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|